image
Healthcare - Biotechnology - NASDAQ - US
$ 0.58
-5.54 %
$ 132 M
Market Cap
-2.23
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one VXRT stock under the worst case scenario is HIDDEN Compared to the current market price of 0.58 USD, Vaxart, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one VXRT stock under the base case scenario is HIDDEN Compared to the current market price of 0.58 USD, Vaxart, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one VXRT stock under the best case scenario is HIDDEN Compared to the current market price of 0.58 USD, Vaxart, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart VXRT

image
$1.0$1.0$0.9$0.9$0.8$0.8$0.7$0.7$0.6$0.6$0.5$0.5$0.4$0.4$0.3$0.3Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
28.7 M REVENUE
288.94%
-66.3 M OPERATING INCOME
20.46%
-66.9 M NET INCOME
18.82%
-44.8 M OPERATING CASH FLOW
36.46%
-21.3 M INVESTING CASH FLOW
-48.52%
56.6 M FINANCING CASH FLOW
271.07%
20.9 M REVENUE
37.48%
-14.9 M OPERATING INCOME
-29.96%
-15.6 M NET INCOME
-30.09%
-9.6 M OPERATING CASH FLOW
-30.69%
13.2 M INVESTING CASH FLOW
27.19%
-164 K FINANCING CASH FLOW
-120.59%
Balance Sheet Vaxart, Inc.
image
Current Assets 68.3 M
Cash & Short-Term Investments 51.7 M
Receivables 12 M
Other Current Assets 4.57 M
Non-Current Assets 98.1 M
Long-Term Investments 0
PP&E 29.1 M
Other Non-Current Assets 69 M
31.09 %7.19 %17.49 %41.48 %Total Assets$166.4m
Current Liabilities 90.9 M
Accounts Payable 6.96 M
Short-Term Debt 3.08 M
Other Current Liabilities 80.8 M
Non-Current Liabilities 16.6 M
Long-Term Debt 14.4 M
Other Non-Current Liabilities 2.14 M
6.48 %2.86 %75.22 %13.45 %Total Liabilities$107.5m
EFFICIENCY
Earnings Waterfall Vaxart, Inc.
image
Revenue 28.7 M
Cost Of Revenue 0
Gross Profit 28.7 M
Operating Expenses 95 M
Operating Income -66.3 M
Other Expenses 655 K
Net Income -66.9 M
30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)29m029m(95m)(66m)(655k)(67m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
84.67% GROSS MARGIN
84.67%
-230.99% OPERATING MARGIN
-230.99%
-233.27% NET MARGIN
-233.27%
-113.62% ROE
-113.62%
-40.24% ROA
-40.24%
-81.49% ROIC
-81.49%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Vaxart, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -66.9 M
Depreciation & Amortization 8.85 M
Capital Expenditures -554 K
Stock-Based Compensation 11.5 M
Change in Working Capital 3.26 M
Others -1.43 M
Free Cash Flow -45.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Vaxart, Inc.
image
VXRT has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 5
6. Ownership
Insider Ownership Vaxart, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
49 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Vaxart Announces Preliminary Results of Annual Meeting of Stockholders SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Preliminary results from the Annual Meeting indicate that two proposals were approved and two proposals were rejected by Vaxart stockholders. globenewswire.com - 2 weeks ago
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology - Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared with first-generation constructs, supporting potential for improved protection against infection - globenewswire.com - 3 weeks ago
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. globenewswire.com - 3 weeks ago
Vaxart Announces Adjournment of Annual Meeting of Stockholders Meeting adjourned to June 13, 2025 at 8:30 a.m. Pacific Time Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m. globenewswire.com - 1 month ago
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025 SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that members of the management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 2:00 PM ET. globenewswire.com - 1 month ago
Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders Dr. Sean Tucker, Founder and CSO of Vaxart, Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on June 1, 2025 Company Corrects Record on Common Misconceptions Regarding the Reverse Stock Split Proposal SOUTH SAN FRANCISCO, Calif. globenewswire.com - 1 month ago
Vaxart Answers Additional Frequently Asked Questions from Retail Investors Company Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on June 1, 2025 SOUTH SAN FRANCISCO, Calif. globenewswire.com - 1 month ago
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial - Study will assess relative efficacy, safety, and immunogenicity of Vaxart's oral pill COVID-19 vaccine candidate against an approved mRNA comparator at 12 months - SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the first patient was dosed in the 10,000-participant portion of its ongoing Phase 2b clinical trial evaluating its oral pill COVID-19 vaccine candidate. globenewswire.com - 1 month ago
Vaxart Announces Adjournment of Annual Meeting of Stockholders Meeting adjourned to June 2, 2025 at 8:30 a.m. Pacific Time Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m. globenewswire.com - 1 month ago
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors approved certain equity awards to the Company's new Chief Financial Officer, Jeroen Grasman, effective May 19, 2025. globenewswire.com - 1 month ago
Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting Company Urges Stockholders to Vote ‘FOR' Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has filed a supplement to its proxy statement for its Annual Meeting. globenewswire.com - 1 month ago
Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), to initiate dosing in the 10,000-participant portion of its ongoing Phase 2b clinical trial evaluating its oral pill COVID-19 vaccine candidate. globenewswire.com - 1 month ago
8. Profile Summary

Vaxart, Inc. VXRT

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 132 M
Dividend Yield 0.00%
Description Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Contact 170 Harbor Way, South San Francisco, CA, 94080 https://vaxart.com
IPO Date Dec. 11, 1981
Employees 105
Officers Mr. Phillip Eric Lee Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer Dr. James F. Cummings M.D. Chief Medical Officer Dr. Sean N. Tucker Ph.D. Senior Vice President & Chief Scientific Officer Dr. Raymond D. Stapleton Jr., Ph.D. Chief Technology Officer Mr. Edward B. Berg Senior Vice President & General Counsel Ms. Laurie Hastings Senior Vice President of Human Resources Ms. Shaily Jaini Garg Senior Vice President of Clinical Development & Project Management Dr. Rajesh Kapoor Ph.D. Senior Vice President of Quality Mr. Steven Lo President, Chief Executive Officer & Director